⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16878031 | 0.97 | — | — | |
| SCHEMBL19541639 | 0.97 | EPAS1 (0.48) | — | |
| SCHEMBL23946276 | 0.92 | — | — | |
| SCHEMBL4904117 | 0.92 | — | — | |
| SCHEMBL14828404 | 0.92 | — | — | |
| SCHEMBL3959007 | 0.90 | EPAS1 (0.47) | — | |
| Hydrochloric Acid SCHEMBL18249041 | 0.89 | — | — | |
| SCHEMBL14158242 | 0.87 | EPAS1 (0.46) | — | |
| SCHEMBL21276522 | 0.84 | EPAS1 (0.42) | — | |
| SCHEMBL4783327 | 0.80 | EPAS1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528828-B2 | Substituted pyrido[4,3-d]pyrimidines as KRAS modulators | ALTEROME THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250346610-A1 | SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS | ALTEROME THERAPEUTICS INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-12466842-B2 | Substituted pyrido [4,3-d]pyrimidines as KRAS modulators | ALTEROME THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250282799-A1 | SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS | ALTEROME THERAPEUTICS, INC. | 2025-09-11 | — | — | US | disclosed |
| US-20250179093-A1 | KRAS MODULATORS | ALTEROME THERAPEUTICS, INC. | 2025-06-05 | — | — | US | disclosed |
| WO-2025064542-A1 | KRAS MODULATORS | ALTEROME THERAPEUTICS, INC. (US) | 2025-03-27 | — | — | WO | disclosed |
| EP-4328310-A1 | SIRNA TARGETING 17B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 AND SIRNA CONJUGATE | Tuojie Biotech (Shanghai) Co., Ltd. (CN) | 2024-02-28 | — | — | EP | disclosed |
| US-20230348371-A1 | SULFONYLUREA DERIVATIVE AND MEDICAL USES THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230287418-A1 | MODIFIED SIRNA WITH REDUCED OFF-TARGET ACTIVITY | TUOJIE BIOTECH(SHANGHAI) CO., LTD. (CN) | 2023-09-14 | — | — | US | disclosed |
| WO-2023141852-A1 | CDK2 INHIBITORS, PREPARATION METHOD THEREFOR AND USE THEREOF | 益方生物科技(上海)股份有限公司 | 2023-08-03 | — | — | WO | disclosed |
| WO-2023109945-A1 | DSRNA, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海拓界生物医药科技有限公司 | 2023-06-22 | — | — | WO | disclosed |
| EP-4194553-A1 | MODIFIED SIRNA WITH REDUCED OFF-TARGET ACTIVITY | Tuojie Biotech (Shanghai) Co., Ltd. (CN) | 2023-06-14 | — | — | EP | disclosed |
| WO-2023001177-A1 | LPA1 SMALL MOLECULE ANTAGONIST | 上海拓界生物医药科技有限公司 | 2023-01-26 | — | — | WO | disclosed |
| WO-2022262855-A1 | MALT1 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海拓界生物医药科技有限公司 | 2022-12-22 | — | — | WO | disclosed |
| WO-2022253294-A1 | PYRIDONE COMPOUND HAVING INTEGRASE INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF | 江苏恒瑞医药股份有限公司 | 2022-12-08 | — | — | WO | disclosed |
| WO-2022135442-A1 | CDK2 INHIBITOR AND PREPARATION METHOD THEREFOR | 上海拓界生物医药科技有限公司 | 2022-06-30 | — | — | WO | disclosed |
| WO-2022135567-A1 | PYRIDAZINE-CONTAINING COMPOUND AND MEDICINAL USE THEREOF | 上海拓界生物医药科技有限公司 | 2022-06-30 | — | — | WO | disclosed |
| WO-2020221294-A1 | BRIDGE RING-3,4-DIHYDRO-PYRIDO[1,2-A]PYRAZINE-1,8-DIONE COMPOUND AND PHARMACEUTICAL USE THEREOF | 上海拓界生物医药科技有限公司 | 2020-11-05 | — | — | WO | disclosed |
| US-20160326157-A1 | MONOBACTAMS AND METHODS OF THEIR SYNTHESIS AND USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-11-10 | — | — | US | disclosed |
| WO-2015103583-A1 | MONOBACTAMS AND METHODS OF THEIR SYNTHESIS AND USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-07-09 | — | — | WO | disclosed |